MCID: CRC006
MIFTS: 48

Carcinoid Syndrome

Categories: Rare diseases, Endocrine diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Carcinoid Syndrome

MalaCards integrated aliases for Carcinoid Syndrome:

Name: Carcinoid Syndrome 50
Carcinoid Tumor 50 29 69
Carcinoid Tumor No Icd-O Subtype 69
Malignant Carcinoid Syndrome 69
Carcinoid Tumor Syndrome 50
Neuroendocrine Tumors 69
Neuroendocrine Tumor 50
Carcinoid Tumors 41

Classifications:



External Ids:

ICD10 33 E34.0

Summaries for Carcinoid Syndrome

NIH Rare Diseases : 50 carcinoid syndrome refers to a group of symptoms that are associated with carcinoid tumors (rare, slow-growing tumors that occur most frequently in the gastroinestinal tract or lungs). affected people may experience skin flushing, abdominal pain, diarrhea, difficulty breathing, rapid heart rate, low blood pressure, skin lesions on the face (telangiectasias), and wheezing. in later stages, carcinoid syndrome may damage the heart valves, resulting in symptoms of congestive heart failure. the condition occurs when the carcinoid tumor secretes serotonin or other chemicals into the bloodstream. only 10% of people with carcinoid tumors develop carcinoid syndrome; most have advanced stage carcinoid tumors that have spread to the liver. treatment generally involves addressing the underlying carcinoid tumor and medications to alleviate symptoms. last updated: 9/25/2015

MalaCards based summary : Carcinoid Syndrome, also known as carcinoid tumor, is related to pheochromocytoma and duodenal carcinoid syndrome. An important gene associated with Carcinoid Syndrome is CHGA (Chromogranin A), and among its related pathways/superpathways are Neuroscience and HIF-1 signaling pathway. The drugs Pancreatic Polypeptide and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and liver, and related phenotypes are growth/size/body region and homeostasis/metabolism

MedlinePlus : 41 carcinoid tumors are rare, slow-growing cancers. they usually start in the lining of the digestive tract or in the lungs. they grow slowly and don't produce symptoms in the early stages. as a result, the average age of people diagnosed with digestive or lung carcinoids is about 60. in later stages the tumors sometimes produce hormones that can cause carcinoid syndrome. the syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. surgery is the main treatment for carcinoid tumors. if they haven't spread to other parts of the body, surgery can cure the cancer.

Wikipedia : 72 Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary... more...

Related Diseases for Carcinoid Syndrome

Diseases related to Carcinoid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
id Related Disease Score Top Affiliating Genes
1 pheochromocytoma 28.0 CALCA CHGA ENO2 MEN1 NPY SST
2 duodenal carcinoid syndrome 11.8
3 carcinoid tumors, intestinal 11.2
4 malignant ovarian mixed epithelial neoplasm 10.9 CHGA SYP
5 primary syphilis 10.9 CHGA SST
6 bone giant cell sarcoma 10.9 CHGA SST
7 spinal cord ependymoma 10.9 CHGA SYP
8 ludwig's angina 10.9 CHGA SYP
9 signet ring cell intrahepatic cholangiocarcinoma 10.8 CHGA SYP
10 esophagus adenocarcinoma 10.8 CHGA SYP
11 basophilic carcinoma 10.8 CHGA SYP
12 wegmann jones smith syndrome 10.8 CALCA SST
13 breast apocrine carcinoma in situ 10.8 SST SYP
14 neurogenic thoracic outlet syndrome 10.8 CHGA SYP
15 diffuse infiltrative lymphocytosis syndrome 10.8 CHGA SYP
16 reticular pattern testicular yolk sac tumor 10.8 CHGA SYP
17 neuritis 10.8 SST SYP
18 renal pelvis carcinoma 10.8 CHGA SST
19 pancreatic neuroendocrine tumor 10.8
20 thyroid sarcoma 10.8 CHGA SYP
21 water-clear cell adenoma 10.8 CALCA SST
22 prolactin producing pituitary tumor 10.7 IGF1 SST
23 central nervous system hematologic cancer 10.7 CHGA SYP
24 neuropathy, hereditary thermosensitive 10.7 CALCA NPY
25 x-linked intellectual disability, porteous type 10.7 CALCA NPY
26 bladder cancer, childhood 10.6 CHGA SST SYP
27 tabes dorsalis 10.6 SST SYP
28 spinal muscular atrophy 10.6 CALCA CHGA SST
29 tricuspid valve insufficiency 10.6 CALCA CHGA SYP
30 chemical colitis 10.6 CHGA PYY
31 lung giant cell carcinoma 10.6 CHGA MEN1 SST
32 mixed cell type adenoma of parathyroid 10.6 CALCA CHGA MEN1
33 brain stem ependymoma 10.6 CHGA MEN1 SYP
34 early-onset parkinson disease 10.6 MEN1 SST SYP
35 2q31.1 microdeletion syndrome 10.6 ENO2 SYP
36 paraganglioma 10.5 CHGA NPY SST
37 glaucomatocyclitic crisis 10.5 IFNA2 SST
38 sporadic hemiplegic migraine 10.5 CALCA CHGA MEN1
39 parathyroid oncocytic adenoma 10.5 CALCA CHGA MEN1
40 intraocular lymphoma 10.5 CHGA MEN1 SST
41 hyperparathyroidism, familial primary 10.5 CALCA CHGA MEN1
42 olfactory nerve neoplasm 10.5 GHRH SYP
43 osteoclast-like giant cell neoplasm of the pancreas 10.5 GHRH SYP
44 congenital mesoblastic nephroma 10.5 CHGA SYP
45 subserous uterine fibroid 10.5 CALCA CHGA MEN1
46 supratentorial primitive neuroectodermal tumor 10.5 CHGA ENO2
47 intestinal volvulus 10.5 NTS PYY SST
48 bile duct cystadenocarcinoma 10.5 NTS PYY SST
49 paranasal sinus cancer 10.5 ENO2 SYP
50 peripheral degeneration of cornea 10.5 NTS PYY SST

Graphical network of the top 20 diseases related to Carcinoid Syndrome:



Diseases related to Carcinoid Syndrome

Symptoms & Phenotypes for Carcinoid Syndrome

MGI Mouse Phenotypes related to Carcinoid Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.9 CHGA ENO2 GHRH HTR3A IGF1 MEN1
2 homeostasis/metabolism MP:0005376 9.65 CHGA GHRH HTR3A IGF1 MEN1 NPY
3 nervous system MP:0003631 9.36 MEN1 NPY NTS PYY SST SYP

Drugs & Therapeutics for Carcinoid Syndrome

Drugs for Carcinoid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
2 Liver Extracts Phase 4,Phase 2,Phase 1
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
5
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
6
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
7
Somatostatin Approved Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
8 lanreotide Approved Phase 3,Phase 2 108736-35-2
9
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
10
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
11
Octreotide Approved, Investigational Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
12
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
14
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
15 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
16 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
17 Antimetabolites Phase 2, Phase 3,Phase 1
18 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
19 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
20 Hormone Antagonists Phase 3,Phase 2,Phase 1
21 Hormones Phase 3,Phase 2,Phase 1
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 3,Phase 2,Phase 1
24 Angiopeptin Phase 3,Phase 2
25 Pharmaceutical Solutions Phase 3,Phase 2
26 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
27 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
28 Antifungal Agents Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
30 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
31 Folate Nutraceutical Phase 2, Phase 3
32 Vitamin B9 Nutraceutical Phase 2, Phase 3
33
Hydroxyurea Approved Phase 2 127-07-1 3657
34
Lenograstim Approved Phase 2 135968-09-1
35
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
36
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
37
Pancrelipase Approved Phase 2 53608-75-6
38
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
39
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
40
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
41
Streptozocin Approved Phase 2 18883-66-4 29327
42
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
43
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
44
Palonosetron Approved, Investigational Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
45
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
46
Floxuridine Approved Phase 2 50-91-9 5790
47
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
48
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
49
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
50
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938

Interventional clinical trials:

(show top 50) (show all 65)

id Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
3 An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
4 Telotristat Etiprate for Carcinoid Syndrome Therapy Completed NCT02063659 Phase 3 Telotristat etiprate tablets (250 mg);Placebo
5 TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Completed NCT01677910 Phase 3 Telotristat etiprate tablets (250 mg);Placebo tablets
6 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
7 Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Active, not recruiting NCT02026063 Phase 3 Telotristat etiprate tablets (250 mg)
8 Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
9 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
10 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Low Dose LX1606 - Day 1 (start);Mid-low dose LX1606 - Day 15 (start);Mid-high dose LX1606 - Day 29 (start);High dose LX1606 - Day 43 (start);4-Week LX1606 Open Label Dose Extension;72-Week LX1606 Open Label Dose Extension
11 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Completed NCT00853047 Phase 2 Low Dose LX1606 Part 1;Mid-Low Dose LX1606 Part 1;Mid-High Dose LX1606 Part 1;High Dose LX1606 Part 1;Part 2 LX1606 Expanded Cohort;Placebo;LX1606 Open Label Dose Extension;LX1606 Open Label Extension 2;LX1606 Open Label Extension 3
12 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
13 Phase II Study of Subcutaneous Injection Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Completed NCT02299089 Phase 2 octreotide FluidCrystal® injection depot
14 Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Completed NCT00002470 Phase 2 fluorouracil
15 Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
16 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
17 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
18 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
19 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
20 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
21 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
22 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
23 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
24 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
25 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
26 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
27 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
28 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Completed NCT00903396 Phase 2 palonosetron hydrochloride
29 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
30 Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors Recruiting NCT01782443 Phase 2 Ziv-aflibercept
31 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
32 A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Active, not recruiting NCT01731925 Phase 2 Lanreotide;Placebo (for sunitinib);Sunitinib
33 Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Active, not recruiting NCT01841736 Phase 2 Pazopanib Hydrochloride
34 YF476 and Type II Gastric Carcinoids Enrolling by invitation NCT02454075 Phase 2 YF476
35 Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome Terminated NCT00884715 Phase 1, Phase 2 Octreotide
36 Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome Terminated NCT01018953 Phase 2 BIM 23A760
37 P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome Terminated NCT01886287 Phase 2 Octreotide LAR
38 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
39 Study of Panitumumab in the Treatment of Carcinoid Syndrome Withdrawn NCT01172717 Phase 2 Panitumumab
40 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
41 An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males Completed NCT01932528 Phase 1 500 mg [14C]-LX1606
42 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
43 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
44 Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT01548482 Phase 1 Temsirolimus
45 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
46 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
47 Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer Completed NCT00003427 Phase 1 irinotecan hydrochloride;oxaliplatin
48 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
49 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
50 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride

Search NIH Clinical Center for Carcinoid Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Carcinoid Syndrome

Genetic tests related to Carcinoid Syndrome:

id Genetic test Affiliating Genes
1 Carcinoid Tumor 29

Anatomical Context for Carcinoid Syndrome

MalaCards organs/tissues related to Carcinoid Syndrome:

39
Heart, Lung, Liver, Skin, Bone, Breast, Testes

Publications for Carcinoid Syndrome

Articles related to Carcinoid Syndrome:

(show top 50) (show all 535)
id Title Authors Year
1
Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? ( 28593854 )
2017
2
Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review. ( 28454406 )
2017
3
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. ( 28238592 )
2017
4
Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. ( 28562131 )
2017
5
Advances in the management of patients with carcinoid syndrome. ( 28591101 )
2017
6
Carcinoid Syndrome and Carcinoid Heart Disease as Manifestations of Non-Metastatic Ovarian Neuroendocrine Tumour. ( 28865508 )
2017
7
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. ( 27918724 )
2017
8
Telotristat ethyl (Xermelo) for carcinoid syndrome diarrhea. ( 28699933 )
2017
9
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. ( 28444114 )
2017
10
Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome. ( 28267211 )
2017
11
Refractory carcinoid syndrome: a review of treatment options. ( 28203303 )
2017
12
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. ( 28642335 )
2017
13
Carcinoid syndrome in neuroendocrine tumors: a prognostic effect? ( 28238598 )
2017
14
Carcinoid Syndrome ( 28846309 )
2017
15
Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - Authors' reply. ( 28593855 )
2017
16
Telotristat ethyl: a new option for the management of carcinoid syndrome. ( 27817224 )
2016
17
Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. ( 26917486 )
2016
18
Endobronchial Carcinoid and Concurrent Carcinoid Syndrome in an Adolescent Female. ( 27895950 )
2016
19
Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. ( 26877616 )
2016
20
The Great Deceiver: A Case of Central Sensitization Presenting as Carcinoid Syndrome. ( 27144900 )
2016
21
Carcinoid Syndrome-Induced Ventricular Tachycardia. ( 27088017 )
2016
22
Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach. ( 27041406 )
2016
23
Coronary artery spasm secondary to carcinoid syndrome. ( 27016533 )
2016
24
Complications from carcinoid syndrome: review of the current evidence. ( 27594907 )
2016
25
Carcinoid syndrome produced by an isolated metastase in femoral nerve from a midgut carcinoid tumor. ( 27026088 )
2016
26
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. ( 27214300 )
2016
27
May depressed and anxious patients with carcinoid syndrome benefit from treatment with selective serotonin reuptake inhibitors (SSRIs)?: findings from a case report. ( 27169982 )
2016
28
Emerging treatment options for carcinoid syndrome. ( 27673284 )
2016
29
Infection with multidrug-resistant Campylobacter coli mimicking recurrence of carcinoid syndrome: a case report of a neuroendocrine tumor patient with repeated diarrhea. ( 27519265 )
2016
30
Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): subgroup analysis of the ELECT study. ( 26431405 )
2015
31
First-in-Human Transcatheter Pulmonic Valve Implantation Through a Tricuspid Valve Bioprosthesis to Treat Native Pulmonary Valve Regurgitation Caused by Carcinoid Syndrome. ( 26315750 )
2015
32
Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. ( 25636046 )
2015
33
Primary Metastatic Small Intestinal Carcinoid Tumor Without Carcinoid Syndrome. ( 26470900 )
2015
34
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor. ( 26600780 )
2015
35
Primary neuroendocrine mediastinal tumor presenting with carcinoid syndrome and left supraclavicular lymphadenopathy. Clinico-radiological and pathological features. ( 26881686 )
2015
36
Intractable hypoglycaemia in a patient with advanced carcinoid syndrome successfully treated with hepatic embolization. ( 26188238 )
2015
37
Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. ( 24676892 )
2014
38
Duodenal carcinoid with carcinoid syndrome. ( 24414187 )
2014
39
Increased chromogranin A and carcinoid syndrome-like symptoms in a patient treated with duloxetine. ( 25100382 )
2014
40
Cognitive impairment associated with carcinoid syndrome. ( 23478527 )
2014
41
Systemic mastocytosis mimicking carcinoid syndrome. ( 24711221 )
2014
42
Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. ( 25096997 )
2014
43
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. ( 25012985 )
2014
44
Carcinoid syndrome caused by a serotonin-secreting pituitary tumour. ( 24174286 )
2014
45
Terminal ileal carcinoid tumor without hepatic or extrahepatic metastasis causing carcinoid syndrome. ( 23574858 )
2013
46
Hypoxia in a patient with carcinoid syndrome. ( 23994395 )
2013
47
Primary neuroendocrine mediastinal tumor presenting with carcinoid syndrome and left supraclavicular lymphadenopathy: clinico-radiological and pathological features. ( 23771374 )
2013
48
Circulating serotonin and bone density, structure, and turnover in carcinoid syndrome. ( 23633214 )
2013
49
Cutaneous scleroderma and malignant carcinoid syndrome. ( 23517363 )
2013
50
Early diffuse coronary artery spasm after heart valve surgery in the carcinoid syndrome. ( 23710535 )
2013

Variations for Carcinoid Syndrome

Expression for Carcinoid Syndrome

Search GEO for disease gene expression data for Carcinoid Syndrome.

Pathways for Carcinoid Syndrome

Pathways related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.97 CALCA ENO2 NPY SYP
2 11.13 ENO2 IGF1 VEGFA
3 10.7 IGF1 SYP VEGFA
4 10.62 NPY PYY

GO Terms for Carcinoid Syndrome

Cellular components related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CALCA CHGA GHRH IFNA2 IGF1 NPY
2 terminal bouton GO:0043195 9.33 CALCA GHRH SYP
3 extracellular space GO:0005615 9.32 CALCA CHGA ENO2 GHRH IFNA2 IGF1

Biological processes related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.67 CALCA NPY PYY
2 movement of cell or subcellular component GO:0006928 9.58 IGF1 NPY PYY
3 regulation of blood pressure GO:0008217 9.54 CALCA CHGA NPY
4 digestion GO:0007586 9.5 NPY PYY SST
5 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.48 GHRH IGF1
6 regulation of appetite GO:0032098 9.43 NPY PYY
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.43 IFNA2 IGF1 VEGFA
8 response to heat GO:0009408 9.33 CALCA IGF1 SST
9 positive regulation of cAMP metabolic process GO:0030816 9.16 CHGA
10 feeding behavior GO:0007631 9.13 CALCA NPY PYY
11 cell-cell signaling GO:0007267 9.02 CALCA GHRH IFNA2 PYY SST

Molecular functions related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.13 NPY NTS PYY
2 hormone activity GO:0005179 9.02 CALCA IGF1 NPY PYY SST

Sources for Carcinoid Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....